Allergy & Immunology Doctors in South Burlington, VT Accepting Medicare

3 Allergy & Immunology doctors found. Showing 1 - 3

Dr. Elizabeth F. Jaffe, MD Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 53 Timber Ln, South Burlington, VT 05403 Phone: 802-864-0294    Fax: 802-864-3779

Dr. Mark Lazarovich, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 53 Timber Ln, South Burlington, VT 05403 Phone: 802-864-0294    Fax: 802-864-3779

Dr. Edward F. Kent Jr., MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 53 Timber Ln, South Burlington, VT 05403 Phone: 802-864-0294    Fax: 802-864-3779

News Archive

Biopharmaceutical companies still trying to find the best ways to measure effectiveness of CAPA processes

A well-defined CAPA system is essential for any biopharmaceutical company to drive quality improvements across the organization. Hence, it is imperative for biopharmaceutical organizations to measure the effectiveness of their CAPA processes to identify potential areas of improvement in their quality function.

Bayer's birth control pills may increase risk of venous thromboembolism

The following release is being issued by law firms RodaNast, P.C.; Levin, Fishbein, Sedran & Berman and Feldman & Pinto: According to two new studies published in the online edition of the British Medical Journal, Bayer's birth control pills Yaz and Yasmin, containing a new progestin drospirenone, carry up to triple the risk of serious blood clots over traditional pills containing the progestin levonorgestrel.

Health law implementation decisions draw state officials' attention, set scene for state-level policy action

Virginia's attorney general outlines his take on the fiscal dangers that the health law's Medicaid expansion will cause. Meanwhile, Michigan lawmakers will consider the creation of a state-based health exchange. Also, in Georgia, a year-long effort to revamp the state's Medicaid program is on hold as one leader says it would be "imprudent" to move forward while so many uncertainties are in play.

Once-daily COPD portfolio data from Novartis presented at European Respiratory Society (ERS) Annual Congress

Novartis announced new analyses of data for once-daily Ultibro® Breezhaler® (investigational QVA149 - indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), which showed significant improvements in lung function, shortness of breath and health-related quality of life for chronic obstructive pulmonary disease (COPD) patients versus all comparators1,2. These data were part of 39 respiratory abstracts presented at the European Respiratory Society (ERS) Annual Congress in Barcelona, Spain.

ISPOR explores digital health technologies to address key health-related challenges

ISPOR, the professional society for health economics and outcomes research-;explored the potential of digital health technologies to address key health-related challenges and how to best evaluate these technologies as the field evolves.

Read more Medical News

› Verified 1 days ago